Regennova operates in the biotechnology sector, focusing on the development of innovative therapies aimed at restoring immune balance in patients suffering from uncontrolled infections or injuries. The company leverages its state-of-the-art peptide discovery platform, known as APEC (A polipo P rotein E C onjugate), to create advanced medical solutions. Regennova primarily serves healthcare providers, research institutions, and pharmaceutical companies looking for cutting-edge treatments to enhance patient outcomes. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, licensing agreements, and direct sales of its therapeutic products.

Keywords: biotechnology, immune balance, peptide discovery, APEC, innovative therapies, healthcare, research institutions, pharmaceutical companies, clinical trials, commercialization.